These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. High frequency of BRAF V600E mutations in ameloblastoma. Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844 [TBL] [Abstract][Full Text] [Related]
5. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study. Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088 [TBL] [Abstract][Full Text] [Related]
6. The molecular basis of odontogenic cysts and tumours. Gomes IP; Bastos VC; Guimarães LM; Gomes CC J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457 [TBL] [Abstract][Full Text] [Related]
7. Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer. Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
9. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331 [TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical and genetic study of BRAF Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma. Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039 [TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669 [TBL] [Abstract][Full Text] [Related]
15. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
16. Ameloblastic fibrosarcoma: a rare malignant odontogenic tumor. Gilani SM; Raza A; Al-Khafaji BM Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):53-6. PubMed ID: 23845294 [TBL] [Abstract][Full Text] [Related]